Prostate-specific membrane antigen (PSMA) serum levels have been proposed to be a better prognostic value than PSA to evaluate the effectiveness of prostate cancer treatments, either via surgery, hormones, radiation, or chemotherapy [88]. Here, FOLH1 is linked to prostate carcinoma.